Mitochondria-targeted Antioxidants as a Prospective Therapeutic Strategy for Multiple Sclerosis
- PMID: 28302008
- DOI: 10.2174/0929867324666170316114452
Mitochondria-targeted Antioxidants as a Prospective Therapeutic Strategy for Multiple Sclerosis
Abstract
Background: Multiple sclerosis (MS) is one of the most widespread chronic neurological diseases that manifests itself by progressive demyelination in the central nervous system. The study of MS pathogenesis begins with the onset of the relapsing-remitting phase of the disease, which becomes apparent due to microglia activation, neuroinflammation and demyelination/ remyelination in the white matter. The following progressive phase is accompanied by severe neurological symptoms when demyelination and neurodegeneration are spread to both gray and white matter. In this review, we discuss a possible role of mitochondrial reactive oxygen species (mtROS) in MS pathogenesis, mechanisms of mtROS generation and effects of some mitochondria-targeted antioxidants as potential components of MS therapy.
Results: In the early phase of MS, mtROS stimulate NLRP3 inflammasomes, which is critical for the formation of local inflammatory lesions. Later, mtROS contribute to blood-brain barrier disruption induced by mediators of inflammation, followed by infiltration of leukocytes. ROS generated by leukocytes and activated microglia promote mitochondrial dysfunction and oligodendrocyte cell death. In the progressive phase, neurodegeneration also depends on excessive mtROS generation. Currently, only a few immunomodulatory drugs are approved for treatment of MS. These drugs mainly reduce the number of relapses but do not stop MS progression. Certain dietary and synthetic antioxidants have demonstrated encouraging results in animal models of MS but were ineffective in the completed clinical trials.
Conclusion: Novel mitochondria-targeted antioxidants could be promising components of combined programs for MS therapy considering that they can be applied at extremely low doses and concurrently demonstrate anti-inflammatory and neuroprotective activities.
Keywords: Multiple sclerosis; demyelination; inflammasome; mitochondria; mitochondria-targeted antioxidants; neuroprotection; oligodendrocytes; reactive oxygen species.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.
Similar articles
-
Antioxidants in multiple sclerosis: do they have a role in therapy?CNS Drugs. 2006;20(6):433-41. doi: 10.2165/00023210-200620060-00001. CNS Drugs. 2006. PMID: 16734496 Review.
-
Therapeutic Effect of the Mitochondria-Targeted Antioxidant SkQ1 on the Culture Model of Multiple Sclerosis.Oxid Med Cell Longev. 2019 Jul 1;2019:2082561. doi: 10.1155/2019/2082561. eCollection 2019. Oxid Med Cell Longev. 2019. PMID: 31354902 Free PMC article.
-
Advances in antioxidative therapy of multiple sclerosis.Curr Med Chem. 2013;20(37):4720-30. doi: 10.2174/09298673113209990156. Curr Med Chem. 2013. PMID: 23834174 Review.
-
Mitochondria-targeted peptide antioxidants: novel neuroprotective agents.AAPS J. 2006 Aug 18;8(3):E521-31. doi: 10.1208/aapsj080362. AAPS J. 2006. PMID: 17025271 Free PMC article. Review.
-
Neuronal injury in chronic CNS inflammation.Best Pract Res Clin Anaesthesiol. 2010 Dec;24(4):551-62. doi: 10.1016/j.bpa.2010.11.001. Epub 2010 Nov 29. Best Pract Res Clin Anaesthesiol. 2010. PMID: 21619866 Review.
Cited by
-
Mitochondrial Medicine: A Promising Therapeutic Option Against Various Neurodegenerative Disorders.Curr Neuropharmacol. 2023;21(5):1165-1183. doi: 10.2174/1570159X20666220830112408. Curr Neuropharmacol. 2023. PMID: 36043795 Free PMC article. Review.
-
Exploring the multifaceted role of NRF2 in brain physiology and cancer: A comprehensive review.Neurooncol Adv. 2023 Dec 23;6(1):vdad160. doi: 10.1093/noajnl/vdad160. eCollection 2024 Jan-Dec. Neurooncol Adv. 2023. PMID: 38221979 Free PMC article. Review.
-
Mitochondrial-derived damage-associated molecular patterns amplify neuroinflammation in neurodegenerative diseases.Acta Pharmacol Sin. 2022 Oct;43(10):2439-2447. doi: 10.1038/s41401-022-00879-6. Epub 2022 Mar 1. Acta Pharmacol Sin. 2022. PMID: 35233090 Free PMC article. Review.
-
New insights in the mechanisms of impaired redox signaling and its interplay with inflammation and immunity in multiple sclerosis.Physiol Res. 2020 Feb 19;69(1):1-19. doi: 10.33549/physiolres.934276. Epub 2019 Dec 19. Physiol Res. 2020. PMID: 31852206 Free PMC article. Review.
-
Intracellular DAMPs in Neurodegeneration and Their Role in Clinical Therapeutics.Mol Neurobiol. 2023 Jul;60(7):3600-3616. doi: 10.1007/s12035-023-03289-9. Epub 2023 Mar 2. Mol Neurobiol. 2023. PMID: 36859688 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical